Home » Stocks » EDAP

EDAP TMS S.A. (EDAP)

Stock Price: $4.05 USD -0.14 (-3.34%)
Updated November 27, 11:31 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 118.02M
Revenue (ttm) 50.46M
Net Income (ttm) 1.70M
Shares Out 29.14M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE 25.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $4.05
Previous Close $4.19
Change ($) -0.14
Change (%) -3.34%
Day's Open 4.14
Day's Range 4.05 - 4.17
Day's Volume 33,368
52-Week Range 1.46 - 5.39

More Stats

Market Cap 118.02M
Enterprise Value 104.29M
Earnings Date (est) Apr 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 29.14M
Float 28.96M
EPS (basic) n/a
EPS (diluted) -0.06
FCF / Share 0.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 2.23%
Payout Ratio n/a
Shares Short 68,817
Short Ratio 0.96
Short % of Float 0.24%
Beta 2.17
PE Ratio n/a
Forward PE 25.25
P/FCF Ratio 44.83
PS Ratio 2.34
PB Ratio 3.97
Revenue 50.46M
Operating Income 2.47M
Net Income 1.70M
Free Cash Flow 2.63M
Net Cash 13.74M
Net Cash / Share 0.47
Gross Margin 46.76%
Operating Margin 4.90%
Profit Margin 3.40%
FCF Margin 5.22%
ROA 2.64%
ROE n/a
ROIC 12.90%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.80*
(43.24% upside)
Low
5.55
Current: $4.05
High
6.05
Target: 5.80
*Average 12-month USD price target from 2 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue44.9139.1835.7535.6132.2526.7924.0826.0722.2923.71
Revenue Growth14.62%9.62%0.38%10.41%20.41%11.23%-7.62%16.93%-5.97%-
Gross Profit21.0016.9214.8116.4113.7911.209.3210.438.869.46
Operating Income2.20-1.32-2.030.390.49-1.74-2.76-2.03-2.50-3.82
Net Income1.51-0.34-0.683.84-1.67-0.51-5.02-7.48-0.94-12.72
Shares Outstanding29.0229.0028.9627.8225.0223.6020.5917.5613.3513.01
Earnings Per Share0.05-0.01-0.020.13-0.07-0.02-0.24-0.43-0.07-0.98
Operating Cash Flow3.791.45-1.371.411.39-0.94-3.25-2.21-0.23-4.52
Capital Expenditures-1.45-1.87-2.07-1.33-0.65-1.02-0.76-0.65-0.87-0.61
Free Cash Flow2.34-0.42-3.440.080.74-1.96-4.01-2.86-1.10-5.13
Cash & Equivalents20.8919.4620.0021.9914.5812.147.688.086.478.89
Total Debt8.666.754.722.764.153.166.549.8411.1914.08
Net Cash / Debt12.2312.7215.2919.2310.438.991.14-1.76-4.72-5.19
Assets53.0748.7446.9046.5938.5832.1526.8730.4432.2435.94
Liabilities25.7123.7821.7422.1424.1517.0117.5922.2823.5327.04
Book Value27.3624.9625.1624.4514.4315.149.288.168.718.90
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name EDAP TMS S.A.
Country France
Employees 216
CEO Marc Oczachowski

Stock Information

Ticker Symbol EDAP
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: EDAP
IPO Date July 31, 1997

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.